Cowen & Co. Reaffirms Their Buy Rating on Voyager Therapeutics Inc (VYGR)

By Carrie Williams

Cowen & Co. analyst Phil Nadeau maintained a Buy rating on Voyager Therapeutics Inc (VYGRResearch Report) today. The company’s shares closed last Monday at $15.40.

According to TipRanks.com, Nadeau is a 3-star analyst with an average return of 1.4% and a 44.4% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical Inc., Phasebio Pharmaceuticals Inc, and Rhythm Pharmaceuticals Inc.

Voyager Therapeutics Inc has an analyst consensus of Strong Buy, with a price target consensus of $30.00.

See today’s analyst top recommended stocks >>

The company has a one-year high of $28.79 and a one-year low of $7.76. Currently, Voyager Therapeutics Inc has an average volume of 387.6K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Voyager Therapeutics, Inc. operates as a clinical-stage gene therapy company, which develops treatments for patients suffering from central nervous system. Its pipeline of gene theraphy programs include VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01.